Document › Details
Boehringer Ingelheim. (12/16/10). "Press Release: Boehringer Ingelheim and Orexo Report Progress in Their Pain and Inflammatory Diseases Collaboration". Uppsala & Ingelheim.
Orexo AB (STO: ORX) and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007. The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases. The selection of a development candidate has triggered a milestone payment of € 6.5 million to Orexo.
The terms of the agreement foresee further potential milestone and royalty payments. Boehringer Ingelheim is responsible for all further compound development and marketing. In the Nordic and Baltic countries Orexo has the option to co-promote the products arising from this collaboration. The co-promotion option would enable Orexo to build up its own commercialisation capabilities within the field of inflammatory pain.
The collaboration is focused on Orexo's initial research on prostaglandin (PG) E2. Prostaglandin E2 (PGE2) is an endogenous substance of the human body that is central to various inflammatory processes. The project is aiming at the development of a medication which specifically targets PGE2 synthesis inhibition. Such selective inhibition could lead to a compound with the potential for fewer side effects than existing pain and inflammation medications, such as the NSAIDs.
"We remain impressed by the quality of Orexo's expertise in the area of arachidonic acid pathways", says Prof. Wolfgang Rettig, Corporate Senior Vice President Research at Boehringer Ingelheim. " The medical need in the area of pain and inflammation is considerable and this collaboration has the potential to address the patients' and physicians' need for a new treatment regarding safety and efficacy."
"We are delighted to report this significant progress in our collaboration with Boehringer Ingelheim, a global player with expertise in the inflammatory pain area and an excellent partner for Orexo. By combining our skills and resources, we are convinced that new and better drugs will sooner be available, for millions of patients," says Dr Torbjörn Bjerke, President and Chief Executive Officer of Orexo."
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. Orexo is developing proprietary products based on its proven reformulation technologies, targeted at the Specialty Pharmaceutical market. Orexo intends to commercialise some of these products itself in one or more major markets. Its development activity builds on Orexo's core competences in R&D, which have previously resulted in several successful products, currently out-licensed through worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which Abstral® is a leading product for the treatment of breakthrough pain in cancer patients in most of Europe.
Orexo also has three significant partnerships with major pharmaceutical companies for research and development programs: discovery stage collaborations with Ortho-McNeil Janssen and Janssen Pharmaceutica in respiratory inflammation and with Boehringer Ingelheim for pain, both within the arachidonic acid cascade and a clinical stage development agreement with Novartis in gastrointestinal disorders.
Orexo's head office is located in Uppsala, Sweden. More information can be found at www.orexo.com
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.
For more information please visit www.boehringer-ingelheim.com
Please be advised
This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the U.S.A.
Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49/6132/77 82 71
Fax +49/6132/77 6601
Record changed: 2014-08-18
More documents for Boehringer Ingelheim (Group)
-  Boehringer Ingelheim. (1/15/15). "Press Release: 35 Partners from Industry and Academia to Join European Research Initiative for the prevention of Alzheimer’s Dementia". Paris....
-  Boehringer Ingelheim. (1/15/15). "Press Release: Boehringer Ingelheim and Sanofi Enter Into a Strategic Contract Manufacturing Alliance to Produce Biopharmaceuticals". Ingelheim....
-  Boehringer Ingelheim. (1/14/15). "Press Release: Boehringer Ingelheim and Vanderbilt University Join Forces to Develop New Ras Inhibitors for Cancer Treatment". Ingelheim....
-  Boehringer Ingelheim. (1/13/15). "Press Release: Boehringer Ingelheim and Yale University Collaborate to Investigate Novel Immunotherapy Targets across Several Therapeutic Areas". Ingelheim....
-  Boehringer Ingelheim. (12/15/14). "Press Release: First Trial of a Novel Oral Anticoagulant Starts in Prevention of Recurrent Stroke Due to a Blood Clot of Undetermined Source [For Non-US/Non-UK/Non-Canadian Media]". Ingelheim....
-  NanoPET Pharma GmbH. (11/30/14). "Pressemitteilung: NanoPET Pharma startet FuE-Partnerschaft mit Boehringer Ingelheim. Know-How von NanoPET verkürzt Entwicklungsdauer neuer Medikamente". Berlin....
-  Boehringer Ingelheim. (10/16/14). "Press Release: Boehringer Ingelheim’s OFEV (nintedanib) Approved by the FDA for the Treatment of Idiopathic Pulmonary Fibrosis [For media outside UK, US and Canada]". Ingelheim....
-  Boehringer Ingelheim. (9/23/14). "Pressemitteilung: Boehringer Ingelheim – Klare Vorgaben zur Kosteneinsparung. Details zum Projekt »Journey« wurden den Mitarbeitern vorgestellt". Ingelheim....
-  Boehringer Ingelheim. (9/18/14). "Press Release: Boehringer Ingelheim and CureVac Announce Collaboration to Develop Next Generation Lung Cancer Immunotherapy". Ingelheim, Tübingen & Ridgefield, CT....
-  Schwarz, Diana [BioRegio STERN]. (9/18/14). "News: Interview mit Dr. Ingmar Hoerr zur Kooperation von CureVac und Boehringer Ingelheim"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSE newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)